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Serum enzyme assays used onfour different analysers (Hitachi 737,
Hitachi 705, Cobas-bio and RA-2X) were compared by determin-
ing the activity ofseven different enzymes (AST, AL T, LD, ALP,
GGT, CK and AMS). Performance checks (quality control
procedure) and replications (the study of the total analytic
imprecision and ofits components) were conducted and the methods
were compared by linear regression analysis with statistical
inference on the curves following the protocols of the National
Committeefor Clinical Laboratory Standards (NCCLS: PSEP-
2, PSEP-3, PSEP-4). The correlation coefficients between the
methods (r 0.991-0.999), together with the other statistical
parameters, indicated that the methods are well correlated on all the
instruments. The total imprecision wasgoodfor all analytes, except
ALT. Among the instruments tested, the RA-2X gave more
variable results, although the total imprecision was acceptable.
There was no relevant carry-over effect. The evaluation of
performance claims indicated that the expected error did not
substantially affect the results at the level ofclinical decisions.
Introduction
Enzyme assays are widely used and play an important
role in laboratory medicine, hence the need for a detailed
analysis of the analytical error and of its various
components, also in relation to the various methods and
instruments that are commercially available and the need
for the commutability of results among various labora-
tories and often even within the same institution. The
most effective method for this type of evaluation remains
the analysis of replicates and the comparison between
methods [1]. Therefore, we studied the analytical error
for seven serum enzymatic activities that are widely used
in clinical diagnostics [AST (aspartate aminotransfer-
ase), ALT (alanine aminotranstrase), LD (lactate dehy-
drogenase), ALP (alkaline phosphatase), GGT (gamma-
glutamyl transferase), CK (creatine kinase) and AMS
Table 1. Imprecision (carry-over included) for the Hitachi 737 (HI), Hitachi 705 (H2), Cobas-Bio (C) and RA-2X (R) (each enzyme
activity was measured at three different levels." low, medium and high).
Imprecision (CV, %)
Mean Between runs,
Analyte (U/l) Within-run within-day Between days Total
H1 H2 C R H H2 C R H1 H2 C R H H C R H1 H9 C R
AST 14 17 16 16
27 31 30 30
176 190 196 167
ALT 9 ll 13 8
14 16 16 13
103 109 108 94
LD 172 164 168 84
310 298 304 149
ALP
GGT
CK
AMS
729 688 739 339
101 106 104 103
199 206 202 202
575 600 592 589
20 19 20 20
30 31 31 31
194 200 197 216
64 59 58 58
104 101 98 98
700 707 691 640
72 69 72 39
138 132 135 82
874 860 864 628
3.8 3.6 4.6 8.8 4.2 2.8 4.1
2.0 1.8 2.5 6.7 2.1 2.0 2.5
0.6 0.8 1.1 1.8 1.9 1.9 1.9
7.2 6.6 8.5 20.3 6.8 6.8 6.5
5.2 4.5 5.9 11.2 5.6 6.7 9.7
0.8 0.6 1.2 3.3 3.6 4.2 3.6
1.3 1.5 3.1 6.6 1.6 1.1 1.8
1.2 3.9 1.6 1.8 1.2 1.5 1.5
1.0 0.6 2.4 1.6 0.9 1.1 2.1
1.8 0.6 1.6 2.5 3.6 1.2 1.6
1.5 0.8 1.5 2.3 1.8 1.2 1.8
1.5 0.5 1.1 1.4 2.9 2.1 1.1
4.4 3.1 2.7 4.6 2.1 2.3 1.9
5.8 2.1 1.8 7.6 1.9 1.6 1.5
0.9 0.7 1.1 1.4 0.9 1.0 0.6
3.5 2.3 4.1 9.2 5.4 1.8 3.3
1.6 2.1 4.1 3.3 4.3 2.1 2.3
0.9 0.5 1.6 5.4 1.1 1.6 1.2
5.3 2.8 1.6 8.9 3.6 3.2 2.1
5.5 1.5 1.2 11.1 5.3 1.1 2.3
0.9 0.6 1.6 1.1 1.2 1.0 0.8
8.2 4.7 4.5 5.2 9.9
4.1 2.7 3.3 3.2 8.8
2.9 3.3 3.4 3.9 5.4
10.2 9.6 10.1 9.8 18.4
8.6 13.4 11.6 11.0 19.2
5.4 10.3 11.1 12.7 13.2
5.9 3.1 2.3 2.1 8.4
2.3 2.2 2.2 2.0 5.7
2.3 2.9 1.8 3.0 3.4
2.1 6.1 3.1 2.7 3.0
1.5 5.4 3.0 2.7 3.2
1.9 5.8 2.9 2.3 3.3
2.7 2.8 4.7 2.9 4.4
3.3 2.6 3.6 3.3 4.2
1.8 1.5 1.2 1.4 3.3
3.4 6.0 3.5 1.7 3.0
2.1 5.2 2.7 3.0 4.9
2.2 3.0 2.4 2.2 4.9
4.3 1.7 3.7 2.6 10.1
5.8 2.5 2.5 1.6 7.3
2.0 1.6 1.7 1.4 2.2
6.1 5.8 6.9 13.3
3.4 3.8 4.0 11.1
3.4 3.5 4.0 5.7
12.0 12.0 12.9 27.4
14.4 12.4 12.4 22.2
10.4 11.2 12.8 13.6
3.3 2.7 3.7 10.7
2.5 4.5 2.6 5.9
3.0 1.9 3.9 3.8
6.4 3.2 3.2 3.9
5.6 3.1 3.1 4.0
6.0 3.0 2.5 3.6
5.2 5.6 3.9 6.4
6.3 4.1 3.8 8.7
1.8 1.4 2.0 3.6
6.9 4.2 4.4 9.7
5.4 3.5 5.1 5.9
3.1 2.5 2.7 7.3
5.6 4.7 3.0 13.4
6.1 2.9 2.0 13.3
1.8 1.8 2.1 2.4
* To whom correspondence should be addressed.
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Figure 1. Comparison between methods on thefour instruments performed by linear regression analysis (n 100) (least-squares method) and
correlation (different analytical methods" were usedfor LD, GGT and AMS assays on the RA-2X).
(amylase)] measured with four instruments [Hitachi 737
and Hitachi 705 (Boehringer Biochemia Robin), Cobas-
Bio (Roche) and RA-2X (Technicon Instruments)].
These instruments were selected because they are rep-
resentative of at least three different approaches. Lastly,
we also compared the Hitachi 737, which is one of the
newest autoanalysers, and its procedures with the other
instruments and their respective procedures.
Experimental
Inslruments
The following were used: Hitachi 737 (Boehringer,
Mannheim, FRG), a discrete, selective multi-channel
analyser; Hitachi 705 (Boehringer), a discrete, selective
multi-channel analyser; Cobas-Bio (Roche, Milan,
Italy), a fast centrifugal analyser; and RA-2X (Techni-
con Instruments, Tarrytown, NY, USA), a discrete,
selective multi-channel analyser in which an inert fluid
(fluorocarbon) is used to prevent cross-contamination.
The Pentalab (Poli, Milan, Italy) statistical software
package was used.
Enzymatic assays
All the catalytic activities were assayed at 37 C. All the
reagents were from Boehringer, except for those used with
the RA-2X, which came from Technicon. The methods
employed for AST, ALT, ALP, CK and LD were
according to SCE (Scandinavian Committee on Enzy-
mes) recommendations [2,3] on all the instruments,
except for the RA-2X where the lactate--pyruvate
reaction was used for LD determination [4]. GGT
activity was determined according to Szasz and Persijn
[5] except on the RA-2X, where SCE recommendations
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were also followed [6]. For the AMS assay, 4-NP-
maltoheptaoside [7] was used as substrate on all instru-
ments except the RA-2X, where maltotetraose was used
[8].
Replication experiment [9]
Pools ofhuman sera at three levels ofconcentration (low,
medium and high) for each enzyme were frozen and used
as required. Two analytical runs were performed each
day (morning and afternoon) for 20 days; each run
consisted of 18 replicate samples. This experiment was
performed to obtain an estimate of the imprecision (total
and of some components) of the test method.
Comparison experiment 10]
Fresh scra were obtained from patients (n 100; 20% at
or below the lowest ’Medical Decision Concentration,’
but within a range of the lowest claimed measurement;
20% in the upper range of response of the measurement
system claimed by the manufacturer; 20% above the
expected ’normal’ range at a ’Medical Decision Concen-
tration;’ 40% in the ’normal’ range). Twenty-five
samples were analysed twice each day, on all the
instruments, within a maximum of 4 h. This experiment
is the basis for making claims about inaccuracy.
Performance check experiment [11]
Commercial lyophilized control sera PN-U (mid-level
concentration) (lot 746) and PP-U (high-level concentra-
tion) (lot 793) from Boehringer were used h after
reconstitution. Three aliquots of each control serum were
included in each run of the comparison and of the
replication experiments, in random order. The perfor-
mance check is intended to ensure that the instrument
performance is consistent with the expected performance
during collection of the experimental data. If for any run
the mean or range of the three mid- and high-level
observations exceed the control limits (established prior
to the experiment), the experimental data of that run
should be discarded as suspected of not representing the
typical performance of the method.
Statistics
The experimental data were elaborated using the Penta-
lab statistical software package, which is based on the
statistical procedures recommended by NCCLS; it can be
used on IBM personal and IBM compatible computers.
Results
Replication
The results of this experiment are given in table 1.
Variance analysis [9] was used to evaluate the total
imprecision, and also the within-series, between-series,
within-day and between-days components. The coeffi-
cients of variation (CV) are acceptable (<10%) for
almost all methods tested on the Hitachi 705, Hitachi 737
and Cobas-Bio instruments; usually the highest CVs
were obtained for low enzyme activity. ALT determina-
tion was affected by a greater variability (always <13%)
because there was a loss ofenzyme activity in serum pools
during the experiment (storage: about 30 days at
-20 C). ALT variability was even greater on the RA-2X
(CV 13-27%), on which instrument higher CVs (always
4%) were also usually obtained for all other methods.
Comparison
The values of the serum enzyme assays obtained with the
Hitachi 737 were plotted against those obtained with the
Hitachi 705, Cobas-Bio and RA-2X instruments, and
were statistically assessed by linear regression analysis
[10]. This statistical approach was used because the
inherent measurement error of method x is compensated
for by the extended range of the data collected (see
Experimental) and can thcrctbrc be ignored. The statistical
significance of the regression equations was evaluated by
means of the standard deviation tiom regression (@),
standard error of the slope (Sb) and of the intercept (So,)
(data not shown). Lastly, the correlation coefficients, r,
were calculated (r 0.991-0.999). The results, which are
shown in figure 1, demonstrate that the methods are well
correlated. The significantly diftirent slopes obtained for
LD and AMS on the RA-2X with respect to the other
instruments tested were in agreement with the use on the
RA-2X of different LD and AMS assay methods, each
procedure having its own reference interval. This also
explains the higher slope detected for GGT on the
RA-2X, but in this instance the discrepancies fell within a
range of values well above the upper reference limit and
were therefore irrelevant for clinical purposes. For ALT
and AST the use of the same calculation factor on
Cobas-Bio led to a theoretical slope for ALT and to a
higher slope for AST; why this happened is not clear, but
in another experiment using a factor for AST different to
that used for ALT we obtained results that were very
satisfactory (data not shown).
Performance check
This test, performed prior to and during the comparison
and the replicate experiments, ensures that the tested
methods were in a stable state of operation. Optimum
CVs for both PN-U and for PP-U (normal and patholog-
ical control sera) were obtained on all the instruments
(CV <5%), except for the RA-2X where higher values
were found (e.g., CV 11.3% for ALT), in agreement
with other reports [12]. The lower variability obtained in
these experiments with respect to the replication experi-
ment (reported in table 1) was obviously due to the
different matrix and storage of the scra employed: in the
first instance (performance check), commercial lyophil-
ized control sera, reconstituted daily and used im-
mediately; and in the second instance (replicate experi-
ments), pooled sera from patients, collected and frozen,
whose aliquots were defrozen and analysed each day. The
numerical data obtained from the experiments described
in this section are not reported for the sake of brevity.
Carry-over
Carry-over was evaluated according to the NCCLS
procedure PSEP-3 [9]. Most of the carry-over values (p)
are <1% (0.3-0.8% on the Hitachi 737; 0.3-0.6% on the
Hitachi 705; 0.4-1.0% on the Cobas-Bio; and 0.6-1.4%
on the RA-2X).
Statement ofperformance claim
The regression line was also used to calculate and verify
the performance claim for the Hitachi 737 (method plus
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Table 2. Performance claims of the Hitachi 737 analyser (y
method) versus the Hitachi 705 (H2), the Cobas-Bio (C) and the
RA-2X (R) analysers (c methods).
Tolerance limits
Xc Total
value* Lower Upper error
analyte Instrument (U/l) (U/l) (U/l) (U/l)
AST H2 60 48 60 12
C 60 43 71 17
R 60 49 73 13
ALT H2 60 52 60 8
C 60 41 67 19
R 6O 54, 68 8
LD H2 300 282 348 48
C 300 272 342 42
R? 150 242 330 180
ALP H2 350 294 406 56
C 350 311 401 51
R 350 278 406 64
GGT H2 50 43 55 7
C 50 38 58 12
R? 50 27 69 23
CK H 100 85 117 17
C 100 82 119 19
R 100 81 119 19
AMS H2 240 211 275 35
C 240 208 276 36
R 130 152 216 86
* Xc Medical Decision Concentration closest to the mean of
the data used for method comparison.
J" Assayed with methods different from those used on the other
instruments.
instrument). This test serves to evaluate the inaccuracy
from the estimate of bias at various Medical Decision
Concentrations [13] and to evaluate inaccuracy plus
imprecision (total error) at the Medical Decision Concen-
tration, Xc, closest to the mean of the data used for
method comparison. To estimate the total error we
calculated, according to the NCCLS PSEP-4 procedure
[10], the tolerance limits, i.e. the range which will (with
95% probability) contain the values of they method in
99% of all similar experiments. The results are given in
table 2. The data indicate that, even under unfavourable
experimental conditions, the expected value with the
Hitachi 737 does not cause substantial alterations in the
clinical decision levels with respect to the other methods.
Discussion and conclusions
The random error evaluated by means of the imprecision
study was similar to those already reported for the
individual instruments for the same analytes 12, 14-16].
The imprecision increased at the lower activity levels for
all the enzymes, as already reported by Schwartz et al.
[12] for the RA-1000. The Hitachi 737, Hitachi 705 and
Cobas-Bio showed a similar imprecision; a higher impre-
cision level was obtained for the RA-2X, but the value
was comparable to data reported [12] for the same type of
instrument. The low CVs (<5%) revealed by the
performance check (replicate determinations of control
sera) confirm the reliability of these instruments for the
assay of the enzymatic activities tested. This finding is
particularly interesting for the last generation instru-
ment, the Hitachi 737, which even with random access
and a greater throughput, produces results that are as
precise as those obtained on the earlier instruments. The
low carry-over values obtained in this study indicate that
the instruments tested are suitable for use in clinical
enzymology. There is a good correlation between the
methods as shown by r values very close to unity. The
comparison method also gave satisfactory results; in
almost all instances the slopes were very near unity
(except, as mentioned above, for LD, AMS and GGT on
the RA-2X, where different procedures were employed),
thus excluding the existence of a relevant bias. Also, the
study of the systematic error at the clinical decision levels
(performance claim) yielded satisfactory results for the
Hitachi 737 compared with the other instruments.
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